CA3202049A1 - Adenosine derivative and pharmaceutical composition comprising the same - Google Patents
Adenosine derivative and pharmaceutical composition comprising the sameInfo
- Publication number
- CA3202049A1 CA3202049A1 CA3202049A CA3202049A CA3202049A1 CA 3202049 A1 CA3202049 A1 CA 3202049A1 CA 3202049 A CA3202049 A CA 3202049A CA 3202049 A CA3202049 A CA 3202049A CA 3202049 A1 CA3202049 A1 CA 3202049A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- bond
- adenosine derivative
- pharmaceutical composition
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163141450P | 2021-01-25 | 2021-01-25 | |
| US63/141,450 | 2021-01-25 | ||
| PCT/US2022/013660 WO2022159872A1 (en) | 2021-01-25 | 2022-01-25 | Adenosine derivative and pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3202049A1 true CA3202049A1 (en) | 2022-07-28 |
Family
ID=82494279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3202049A Pending CA3202049A1 (en) | 2021-01-25 | 2022-01-25 | Adenosine derivative and pharmaceutical composition comprising the same |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11793827B2 (https=) |
| EP (1) | EP4281081A4 (https=) |
| JP (1) | JP7843289B2 (https=) |
| KR (1) | KR20230132476A (https=) |
| CN (1) | CN116710465A (https=) |
| AU (1) | AU2022210781A1 (https=) |
| CA (1) | CA3202049A1 (https=) |
| IL (1) | IL304366A (https=) |
| MX (1) | MX2023008004A (https=) |
| TW (1) | TW202245805A (https=) |
| WO (1) | WO2022159872A1 (https=) |
| ZA (1) | ZA202408803B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3146679A1 (en) | 2019-07-27 | 2021-02-04 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| EP4281081A4 (en) | 2021-01-25 | 2025-05-14 | Brii Biosciences, Inc. | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF |
| EP4281083A4 (en) | 2021-01-25 | 2025-01-01 | Brii Biosciences, Inc. | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS |
| CR20250310A (es) * | 2023-01-30 | 2025-08-25 | Merck Sharp & Dohme Llc | Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4' |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3407191A (en) * | 1966-08-29 | 1968-10-22 | Lilly Co Eli | Adamantoate esters of nucleosides |
| US5880154A (en) | 1994-02-01 | 1999-03-09 | The Board Of Regents Of The University Of Nebraska | Polymeric adamantane analogues |
| JP2007504232A (ja) | 2003-09-05 | 2007-03-01 | アナディス ファーマシューティカルズ インク | Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与 |
| CA2502109C (en) | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| WO2007022073A2 (en) | 2005-08-12 | 2007-02-22 | Merck & Co., Inc. | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
| WO2008011406A2 (en) | 2006-07-18 | 2008-01-24 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
| WO2011058582A1 (en) | 2009-11-16 | 2011-05-19 | Orchid Research Laboratories Ltd. | Histone deacetylase inhibitors for the treatment of fungal infections |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| MX391226B (es) * | 2015-09-23 | 2025-03-21 | Merck Sharp & Dohme Llc | Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos. |
| US20180030080A1 (en) * | 2016-07-28 | 2018-02-01 | Alexandre Vasilievich Ivachtchenko | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use |
| US10266558B2 (en) * | 2016-10-07 | 2019-04-23 | Alexandre Vasilievich Ivachtchenko | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |
| RU2659388C1 (ru) * | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
| DK3590924T3 (da) | 2017-02-28 | 2022-01-03 | Kangpu Biopharmaceuticals Inc | Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf |
| US20190185508A1 (en) * | 2017-12-15 | 2019-06-20 | Merck Sharp & Dohme Corp. | Deuterated nucleoside reverse transcriptase inhibitors |
| EP3762396A1 (en) | 2018-03-07 | 2021-01-13 | GlaxoSmithKline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
| CN109053803A (zh) | 2018-07-04 | 2018-12-21 | 米文君 | 一类新的化合物及其用途 |
| AU2019317810A1 (en) * | 2018-08-09 | 2021-02-25 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in HIV therapy |
| JP2021536444A (ja) | 2018-08-30 | 2021-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Ｈｉｖ療法に有用な化合物 |
| CN113811360A (zh) | 2019-03-06 | 2021-12-17 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 用于hiv治疗的化合物 |
| CA3146679A1 (en) | 2019-07-27 | 2021-02-04 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| WO2021038509A1 (en) | 2019-08-28 | 2021-03-04 | Glaxosmithkline Intellectual Property (No.2) Limited | 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy |
| KR20220066303A (ko) | 2019-09-11 | 2022-05-24 | 더 스크립스 리서치 인스티튜트 | 항바이러스 전구약물 및 이의 약제학적 조성물 |
| EP4281081A4 (en) | 2021-01-25 | 2025-05-14 | Brii Biosciences, Inc. | ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF |
| EP4281083A4 (en) | 2021-01-25 | 2025-01-01 | Brii Biosciences, Inc. | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS |
-
2022
- 2022-01-25 EP EP22743369.5A patent/EP4281081A4/en active Pending
- 2022-01-25 WO PCT/US2022/013660 patent/WO2022159872A1/en not_active Ceased
- 2022-01-25 JP JP2023543239A patent/JP7843289B2/ja active Active
- 2022-01-25 MX MX2023008004A patent/MX2023008004A/es unknown
- 2022-01-25 CA CA3202049A patent/CA3202049A1/en active Pending
- 2022-01-25 CN CN202280009277.3A patent/CN116710465A/zh active Pending
- 2022-01-25 KR KR1020237024605A patent/KR20230132476A/ko active Pending
- 2022-01-25 US US17/583,805 patent/US11793827B2/en active Active
- 2022-01-25 AU AU2022210781A patent/AU2022210781A1/en active Pending
- 2022-01-25 TW TW111103173A patent/TW202245805A/zh unknown
-
2023
- 2023-07-10 IL IL304366A patent/IL304366A/en unknown
- 2023-09-15 US US18/467,985 patent/US12390484B2/en active Active
-
2024
- 2024-11-20 ZA ZA2024/08803A patent/ZA202408803B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12390484B2 (en) | 2025-08-19 |
| KR20230132476A (ko) | 2023-09-15 |
| AU2022210781A9 (en) | 2024-10-10 |
| US20220233567A1 (en) | 2022-07-28 |
| EP4281081A1 (en) | 2023-11-29 |
| ZA202408803B (en) | 2025-06-25 |
| JP2024503723A (ja) | 2024-01-26 |
| IL304366A (en) | 2023-09-01 |
| CN116710465A (zh) | 2023-09-05 |
| TW202245805A (zh) | 2022-12-01 |
| EP4281081A4 (en) | 2025-05-14 |
| JP7843289B2 (ja) | 2026-04-09 |
| US11793827B2 (en) | 2023-10-24 |
| MX2023008004A (es) | 2023-07-13 |
| WO2022159872A1 (en) | 2022-07-28 |
| US20240245716A1 (en) | 2024-07-25 |
| AU2022210781A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12370208B2 (en) | Adenosine derivative and pharmaceutical composition comprising the same | |
| CA3202049A1 (en) | Adenosine derivative and pharmaceutical composition comprising the same | |
| JP6563585B2 (ja) | 抗ウイルス性ベータ−アミノ酸エステルホスホジアミド化合物 | |
| EP3558322B1 (en) | Antiviral benzyl-amine phosphodiamide compounds | |
| JP2018531216A6 (ja) | 抗ウイルス性ベータ−アミノ酸エステルホスホジアミド化合物 | |
| JP2020504733A (ja) | テノホビルの抗ウイルス性脂肪族エステルプロドラッグ | |
| AU2021206100B2 (en) | Polycyclic compound acting as kinase inhibitor | |
| EA051612B1 (ru) | Производное аденозина и содержащая его фармацевтическая композиция | |
| US11826375B2 (en) | Phosphinic amide prodrugs of tenofovir | |
| RU2824528C2 (ru) | Аденозиновое производное и фармацевтическая композиция, содержащая его | |
| HK40074714B (zh) | 腺苷衍生物和包含其的药物组合物 | |
| HK40074714A (en) | Adenosine derivative and pharmaceutical composition comprising the same | |
| TW202434594A (zh) | ４＇－經取代之核苷反轉錄酶抑制劑之前藥 | |
| TW202517253A (zh) | Cdk2抑制劑及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241219 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241219 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241219 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251210 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260126 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260127 |